Compare Stocks → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATXINASDAQ:BLCMNASDAQ:CYTONASDAQ:PHIOOTCMKTS:PVOTF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.13$0.15$0.11▼$1.25$5.96M-0.244.59 million shs290,143 shsBLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsCYTOAltamira Therapeutics$1.50+1.4%$1.90$1.42▼$28.40$2.37M1.791.00 million shs23,428 shsPHIOPhio Pharmaceuticals$0.64-1.6%$0.79$0.50▼$6.85$2.92M1.44282,756 shs61,688 shsPVOTFBetterLife Pharma$0.13$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+2.66%-9.69%-15.56%-6.83%-87.49%BLCMBellicum Pharmaceuticals0.00%0.00%0.00%-29.13%-85.51%CYTOAltamira Therapeutics-9.20%-26.00%-12.43%-38.33%-93.78%PHIOPhio Pharmaceuticals-1.94%-5.94%-34.55%+1.07%-86.93%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%Chances are you know the firms on this list (Ad)These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…That’s exactly how this expert trader plans to trade his #1 ticker for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXIAvenue TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals2.3992 of 5 stars3.55.00.00.00.02.50.6PVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics3.00BuyN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/APHIOPhio Pharmaceuticals3.00Buy$4.00529.92% UpsidePVOTFBetterLife PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest ATXI, BLCM, CYTO, PVOTF, and PHIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/6/2024PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$0.03 per shareN/ABLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33CYTOAltamira Therapeutics$320K7.41N/AN/A$4.56 per share0.33PHIOPhio PharmaceuticalsN/AN/AN/AN/A$2.06 per shareN/APVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$1.27N/A∞N/AN/AN/A-335.11%5/10/2024 (Estimated)BLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ACYTOAltamira Therapeutics-$4.31MN/A0.00∞N/AN/AN/AN/A7/10/2024 (Estimated)PHIOPhio Pharmaceuticals-$10.83M-$5.93N/A∞N/AN/A-134.66%-105.86%5/9/2024 (Estimated)PVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/ALatest ATXI, BLCM, CYTO, PVOTF, and PHIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023ATXIAvenue TherapeuticsN/A$0.56+$0.56$0.56N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/ABLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A1.551.55BLCMBellicum PharmaceuticalsN/A3.043.04CYTOAltamira TherapeuticsN/A1.381.38PHIOPhio PharmaceuticalsN/A5.705.71PVOTFBetterLife PharmaN/A3.623.62OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%BLCMBellicum Pharmaceuticals4.93%CYTOAltamira Therapeutics1.91%PHIOPhio Pharmaceuticals57.31%PVOTFBetterLife PharmaN/AInsider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%BLCMBellicum Pharmaceuticals10.30%CYTOAltamira Therapeutics13.03%PHIOPhio Pharmaceuticals0.77%PVOTFBetterLife Pharma34.77%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics344.26 million43.46 millionNot OptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableCYTOAltamira Therapeutics101.58 million1.37 millionNot OptionablePHIOPhio Pharmaceuticals94.59 million4.56 millionNot OptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableATXI, BLCM, CYTO, PVOTF, and PHIO HeadlinesSourceHeadlineJardiance and Ofev propel Boehringer’s human pharma salesmsn.com - April 17 at 2:48 PMVertex Pharma scientist talks about the long road to developing non-addictive painkillersabcnews.go.com - April 15 at 12:36 PMPharmacy defends Eli Lilly off-label drug suitlifesciencesipreview.com - April 11 at 2:26 PMBetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferencetmcnet.com - April 11 at 9:26 AMVictory Over Big Pharma Will Take More Than the IRAmsn.com - April 4 at 8:20 PMLiberals Need to Be Radicalsprospect.org - April 4 at 10:19 AMPharma is betting big on connecting potential patients to its medications. It's just the beginningendpts.com - April 3 at 2:37 AMAEVIS VICTORIA SA - Fabrice Zumbrunnen to become…pharmiweb.com - March 13 at 4:50 AMPresence of Particulates Prompts Recall of Treprostinil Injectionempr.com - March 13 at 4:50 AMIn Vietnam’s Mekong Delta, the lure of moving to the city grows even stronger amid climate shockskdvr.com - March 12 at 10:24 PMAmerica’s Last Top Modelsnewyorker.com - March 12 at 10:24 PMProfile: Xi Jinping the reformerchinadaily.com.cn - March 12 at 12:23 PMBetterLife Pharma Inc.: BetterLife's 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton Universityfinanznachrichten.de - March 4 at 1:49 PMIndia continues fast economic growth but FDI falls sharplyglobal.chinadaily.com.cn - March 1 at 8:26 AMGenesisCare Completes Reorganisation and Emerges from Chapter 11pharmiweb.com - February 19 at 3:51 PMImmigrant Execs Give Back to OCocbj.com - February 5 at 9:25 PMThe tragedy of Leonard Farruku, the gifted young musician whose dream of a better life ended on the Bibby Stockholmtheguardian.com - February 5 at 9:25 PMWeight loss drugs could create the first $1 trillion pharma companiesmsn.com - February 1 at 9:57 AMRoff: Medicare prescription price controls will hurt seniorsnews-journal.com - January 31 at 11:57 PMBudget 2024 Live Updates: Infrastructure, income tax, fiscal deficit, job creation announcements expected from FM Sitharaman's Union Budgettimesofindia.indiatimes.com - January 31 at 11:57 PMBetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001finance.yahoo.com - January 2 at 10:19 AMBig Pharma scrambles to feed demand for weight-loss treatments amid rising U.S. obesity ratesnbcnewyork.com - November 16 at 5:01 PMBig Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity ratesmsn.com - November 16 at 12:01 PMUS Patent and Trademark Office Publishes BetterLife's Comprehensive Patent for BETR-001 and Other LSD Derivativestmcnet.com - November 15 at 12:13 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvenue TherapeuticsNASDAQ:ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.Bellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Altamira TherapeuticsNASDAQ:CYTOAltamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Phio PharmaceuticalsNASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.BetterLife PharmaOTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.